KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Pacira BioSciences (PCRX) over the last 10 years, with Dec 2024 value amounting to -$4.5 million.

  • Pacira BioSciences' Gains from Investment Securities rose 99.30% to $16.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.9 million, marking a year-over-year decrease of 76.20%. This contributed to the annual value of -$4.5 million for FY2024, which is 30.17% down from last year.
  • Latest data reveals that Pacira BioSciences reported Gains from Investment Securities of -$4.5 million as of FY2024, which was down 30.17% from -$3.4 million recorded in FY2023.
  • Pacira BioSciences' 5-year Gains from Investment Securities high stood at $5.2 million for FY2020, and its period low was -$29.5 million during FY2022.
  • Its 3-year average for Gains from Investment Securities is -$12.5 million, with a median of -$4.5 million in 2024.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first slumped by 1,206.87% in 2022, then spiked by 88.38% in 2023.
  • Over the past 5 years, Pacira BioSciences' Gains from Investment Securities (Yearly) stood at $5.2 million in 2020, then slumped by 48.83% to $2.7 million in 2021, then plummeted by 1,206.87% to -$29.5 million in 2022, then spiked by 88.38% to -$3.4 million in 2023, then slumped by 30.17% to -$4.5 million in 2024.